The Roles of Cancer Stem Cells and Therapy Resistance in Colorectal Carcinoma
Open accessThe DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.
Abstract
Cancer stem cells (CSCs) are the main culprits involved in therapy resistance and disease recurrence in colorectal carcinoma (CRC). Results using cell culture, animal models and tissues from patients with CRC suggest the indispensable roles of colorectal CSCs in therapeutic failure. Conventional therapies target proliferating and mature cancer cells, while CSCs are mostly quiescent and poorly differentiated, thereby they can easily survive chemotherapeutic insults. The aberrant activation of Wnt/β-catenin, Notch, Hedgehog, Hippo/YAP (Yes-associated protein) and phosphatidylinositol 3-kinase/protein kinase B facilitates CSCs with excessive self-renewal and therapy resistance property in CRC. CSCs survive the chemo-radiotherapies by escaping therapy mediated DNA damage via altering the cell cycle checkpoints, increasing DNA damage repair capacity and by an efficient scavenging of reactive oxygen species. Furthermore, dysregulations of miRNAs e.g., miR-21, miR-93, miR-203, miR-215, miR-497 etc., modulate the therapeutic sensitivity of colorectal CSCs by regulating growth and survival signalling. In addition, a reversible quiescent G0 state and the re-entering cell cycle capacity of colorectal CSCs can accelerate tumour regeneration after treatment. Moreover, switching to favourable metabolic signatures during a therapeutic regimen will add more complexity in therapeutic outcomes against CSCs. Therapeutic strategies targeting these underlying mechanisms of CSCs’ therapy resistance could provide a promising outcome, however, deep understanding and concerted research are necessary to design novel therapies targeting CSCs. To conclude, the understanding of these mechanisms of CSC in CRC could lead to the improved management of patients with CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While conventional therapies target rapidly proliferating and more differentiated cancer cells, CSCs are slow-growing or quiescent and poorly differentiated [70].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [70]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, CSCs can adapt in response to chemotherapy and radiotherapy by altering cell cycle checkpoints, by inducing cell cycle arrest (reversible quiescent G0 state), or by efficient scavenging of ROS [70].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [70]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Loss of Hmga1 gene function affects embryonic stem cell lymphohematopoietic differentiation
Battista, S., Pentimalli, F., Baldassarre, G., Fedele, M., Fidanza, V., Croce, C. M., & Fusco, A. (2003) · The FASEB Journal · doi:10.1096/fj.02-0977fje · Cited by 69 · cited 1×
“HMGA1is a master regulator in both CSCs [83,84] and normal embryonic stem cells [84,85].”
RetractedMultidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 1×
“For example, mutations in key signalling pathway molecules, the increased expression of anti-apoptotic proteins, the presence of quiescent and/or resistant tumour cells or the over-activation of drug efflux pumps are all potential causes of therapy failure [4,5].”
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“For example, mutations in key signalling pathway molecules, the increased expression of anti-apoptotic proteins, the presence of quiescent and/or resistant tumour cells or the over-activation of drug efflux pumps are all potential causes of therapy failure [4,5].”
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555 · cited 4×
“The pharmacological intervention of ROS scavenging property in CSCs could significantly decrease their clonogenicity and resulted in increased in sensitization of cancer cells to radiotherapy [57].”
InfluentialPark, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272 · cited 2×
“These differential expressed miRNAs, such as miR-451, miR-429 and miR-155, are associated with the differentiation and EMT process in CSCs [65,66].”
miR-34a repression of SIRT1 regulates apoptosis
Yamakuchi, M., Ferlito, M., & Lowenstein, C. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801613105 · Cited by 1,342 · cited 16×
“Interestingly, miR-34 regulates the expression of SIRT1, and therefore, could be utilized against SIRT1 [100,103].”
InfluentialColon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4
Todaro, M., Alea, M. P., Di Stefano, A. B., Cammareri, P., Vermeulen, L., Iovino, F., Tripodo, C., Russo, A., Gulotta, G., Medema, J. P., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.08.001 · Cited by 1,039 · cited 2×
“An increase of CD133+ tumour cells (CSCs’ phenotype) has been found after oxaliplatin treatment in xenotransplanted colon cancer cells [24].”
ABC transporters in cancer: more than just drug efflux pumps
Fletcher, J. I., Haber, M., Henderson, M. J., & Norris, M. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2789 · Cited by 1,018 · cited 1×
“These quiescent CSCs can re-enter the cell cycle after treatment and can accelerate tumour regeneration by activating cell growth and proliferative signalling pathways [11,81].”
Exploring the role of cancer stem cells in radioresistance
Baumann, M., Krause, M., & Hill, R. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2419 · Cited by 815 · cited 2×
“Furthermore, these CSCs are also resistant to radiotherapy [12].”
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801 · cited 1×
“The activation of the PI3K/AKT pathway is associated with cancer therapy-associated resistances in many human malignancies, including CRC [44].”
Cited by
Sethy, C., & Kundu, C. N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111285 · Cited by 539
Colorectal liver metastasis: molecular mechanism and interventional therapy
Zhou, H., Liu, Z., Wang, Y., Wen, X., Amador, E. H., Yuan, L., Ran, X., Xiong, L., Ran, Y., Chen, W., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00922-2 · Cited by 298
Azwar, S., Seow, H. F., Abdullah, M., Faisal Jabar, M., & Mohtarrudin, N. (2021) · Biology · doi:10.3390/biology10090854 · Cited by 173
“These include raised Bcl-2 and Bcl-xL that inhibit apoptosis [106,107]; higher expression of ABC transporters such as ABCC2, ABCC3, and ABCG2 that promote drug export from the cell [20,108]; overexpression of DNA repair gene O6-methylguanine-DNA-methyltransferase (MGMT) [109,110]; and the alteration of cell cycle chec…”
BackgroundMiao, Z., Zhao, X., & Liu, X. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113439 · Cited by 138
Far, B. F., Vakili, K. G., Fathi, M., Yaghoobpoor, S., Bhia, M., & Naimi‐Jamal, M. R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121340 · Cited by 121
Advances of Wnt Signalling Pathway in Colorectal Cancer
Zhu, Y., & Li, X. (2023) · Cells · doi:10.3390/cells12030447 · Cited by 109
The paradigm of drug resistance in cancer: an epigenetic perspective
Adhikari, S., Bhattacharya, A., Adhikary, S., Singh, V., Gadad, S. S., Roy, S., & Das, C. (2022) · Bioscience Reports · doi:10.1042/bsr20211812 · Cited by 96
Keyvani‐Ghamsari, S., Khorsandi, K., Rasul, A., & Zaman, M. K. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01107-4 · Cited by 94
“In addition, due to the ability to change the cell cycle checkpoints and the efficient DNA damage repair system thereof, CSCs have high survival capacity, which makes them resistant to chemotherapy drugs such as cisplatin, oxaliplatin, doxorubicin, daunorubicin and methotrexate [7, 16].”
BackgroundMicroRNA-21's role in PTEN suppression and PI3K/AKT activation: Implications for cancer biology
Chawra, H. S., Agarwal, M., Mishra, A., Chandel, S. S., Singh, R. P., Dubey, G., Kukreti, N., & Singh, M. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155091 · Cited by 91
Lipid-Based Drug Delivery Nanoplatforms for Colorectal Cancer Therapy
Yang, C., & Merlin, D. (2020) · Nanomaterials · doi:10.3390/nano10071424 · Cited by 82
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“In addition, CSCs can adapt in response to chemotherapy and radiotherapy by altering cell cycle checkpoints, by inducing cell cycle arrest (reversible quiescent G 0 state), or by efficient scavenging of ROS [70].”
Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms
Guo, J., Zhao, J., Fu, W., Xu, Q., & Huang, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.918314 · Cited by 79
Zhu, G.-X., Gao, D., Shao, Z., Chen, L., Ding, W., & Yu, Q. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11744 · Cited by 78
“Notably, Wnt/β‐catenin signaling has been reported to regulate the formation of CRC via these three aspects (23,24).”
BackgroundHuang, C., Zhou, Y., Feng, X., Wang, J., Li, Y., & Yao, X. (2023) · ACS Nano · doi:10.1021/acsnano.3c00668 · Cited by 77
Liao, W., Zhang, L., Chen, X., Xiang, J., Zheng, Q., Chen, N., Zhao, M., Zhang, G., Xiao, X., Zhou, G. Q., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154524 · Cited by 76
Nanog mediated by FAO/ACLY signaling induces cellular dormancy in colorectal cancer cells
Zhang, M., Peng, R., Wang, H., Yang, Z., Zhang, H., Zhang, Y., Wang, M., Wang, H., Lin, J., Zhao, Q., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04606-1 · Cited by 74
Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 74
Berberine is a suppressor of Hedgehog signaling cascade in colorectal cancer
Sun, Q., Tao, Q., Ming, T., Tang, S., Zhao, H., Liu, M., Yang, H., Ren, S., Lei, J., Liang, Y., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154792 · Cited by 74
Andrade, F., Rafael, D. F. D. S., Vilar-Hernández, M., Montero, S., Martínez-Trucharte, F., Seras‐Franzoso, J., Díaz‐Riascos, Z. V., Boullosa, A., García‐Aranda, N., Cámara‐Sánchez, P., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.022 · Cited by 72
Akbar, M. U., Khattak, S., Khan, M. I., Saddozai, U. A. K., Ali, N., Alasmari, A. F., Zaheer, M., & Badar, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1265440 · Cited by 71
“The metal nodes in MOFs also act as catalytic centers performing peroxidase-like (POD) reactions to induce reactive oxygen species (ROS) mediated stress in cancer cells for chemodynamic therapy (Di et al., 2023).”
Racial and Ethnic Disparities in Early-Onset Colorectal Cancer Survival
Zaki, T. A., Liang, P. S., May, F. P., & Murphy, C. C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.05.035 · Cited by 70
Ji, Z., Tian, W., Gao, W., Zang, R., Wang, H., & Yang, G. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.684505 · Cited by 68
“The CSC hypothesis states that CSCs possess some of the biological properties of normal stem cells, including indefinite self-replication, asymmetric cell division, and resistance to toxic agents (De Francesco et al., 2018; Najafi et al., 2019).”
BackgroundRecent advances in targeted drug delivery systems for resistant colorectal cancer
Sharifi-Azad, M., Fathi, M., Cho, W. C., Barzegari, A., Dadashi, H., Dadashpour, M., & Jahanban-Esfahlan, R. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02605-y · Cited by 65
“Other key pathways attributed to higher maintenance of CSC as well as increased cellular growth, survival, chemoresistance, increased cancer recurrence and metastasis include Notch, Hedgehog, PI3K/AKT, and Hippo/Yap [37].”
BackgroundKasprzak, A. (2023) · Cancers · doi:10.3390/cancers15184570 · Cited by 61
“The main culprits of treatment resistance, metastasis, and relapse in CRC appear to be CSCs [92,93].”
Qiao, L., Chen, Y., Liang, N., Xie, J. W., Deng, G., Chen, F., Wang, X., Liu, F., Li, Y., & Zhang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.775238 · Cited by 60
Wnt-Independent and Wnt-Dependent Effects of APC Loss on the Chemotherapeutic Response
Stefanski, C. D., & Prosperi, J. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217844 · Cited by 59
Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer
Cotino‐Nájera, S., Herrera, L. A., Domínguez-Gómez, G., & Díaz‐Chávez, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1287505 · Cited by 58
Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited
Hall, D. C. N., & Benndorf, R. A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04430-y · Cited by 54
“Most cancer therapies, such as radiation and chemotherapeutic drugs, target replication mechanisms of highly proliferating cells, such as cancer cells [252, 253].”
BackgroundInfluentialCancer stem cells targets and combined therapies to prevent cancer recurrence
Raghav, P. K., & Mann, Z. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119465 · Cited by 53
Sphyris, N., Hodder, M. C., & Sansom, O. J. (2021) · Cancers · doi:10.3390/cancers13051000 · Cited by 52
O-GlcNAcylation regulation of cellular signaling in cancer
Ciraku, L., Esquea, E. M., & Reginato, M. J. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110201 · Cited by 52
Słoka, J., Madej, M., & Strzałka‐Mrozik, B. (2023) · Molecules · doi:10.3390/molecules28135081 · Cited by 49
Kubatka, P., Kello, M., Kajo, K., Samec, M., Líšková, A., Jašek, K., Koklesová, L., Kuruc, T., Adamkov, M., Šmejkal, K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010183 · Cited by 49
Sukocheva, O. A., Liu, J., Неганова, М. Е., Beeraka, N. M., Aleksandrova, Y. R., Manogaran, P., Grigorevskikh, E., Chubarev, V. N., & Fan, R. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.012 · Cited by 49
Zhu, Y., Gu, L., Lin, X., Zhang, J., Tang, Y., Zhou, X., Lu, B., Lin, X., Liu, C., Prochownik, E. V., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150607 · Cited by 46
“However, directly repressing β-catenin was found to have on-target toxicity to humans, and there is still no candidate for a drug target to treat CRC (56, 58).”
BackgroundTargeting cancer stem cells with polymer nanoparticles for gastrointestinal cancer treatment
Sun, Y., Li, B., Cao, Q., Liu, T., & Li, J. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03180-9 · Cited by 46
Fattahi, F., Zanjani, L. S., Shams, Z. H., Kiani, J., Mehrazma, M., Najafi, M., & Madjd, Z. (2021) · Scientific Reports · doi:10.1038/s41598-021-92720-z · Cited by 45
The Significance of Exosomes in Pathogenesis, Diagnosis, and Treatment of Esophageal Cancer
Jing, Z., Chen, K., & Gong, L. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s321555 · Cited by 44
Huang, C., Zhou, Y., Tong, Q., Duan, Q.-J., Zhang, Q. H., Du, J., & Yao, X. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121827 · Cited by 40
Nanoparticles: The future of effective diagnosis and treatment of colorectal cancer?
Naeimi, R., Najafi, R., Molaei, P., Amini, R., & Pecic, S. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175350 · Cited by 40
Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing
Zarif, T. E., Yibirin, M., Oliveira-Gomes, D. D., Machaalani, M., Nawfal, R., Carlini, G. B., Bahmad, H. F., & Bitar, N. (2022) · Cancers · doi:10.3390/cancers14092105 · Cited by 39
“In patients with stage II CRC with a high risk of recurrence after surgery or stage III disease (lymph node metastases), adjuvant chemotherapy using oxaliplatin and irinotecan in addition to 5-fluorouracil (5FU) or Capecitabine is used [9].”
MethodWang, P., Deng, Z., Li, A., Li, R., Huang, W., Cui, J., Chen, S., Li, B., & Zhang, S. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00839-4 · Cited by 38
Ibrahim, I. A. A., Alzahrani, A. R., Alanazi, I. M., Shahzad, N., Shahid, I., Falemban, A. H., Azlina, M. F. N., & Arulselvan, P. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126581 · Cited by 37
Huang, X., Chen, C., Xie, W., Zhou, C., Tian, X. W., Zhang, Z., Wang, Q., Chang, H., Xiao, W., Zhang, R., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.06.2515 · Cited by 36
Chang, Y.-H., Zhang, J., Huo, X., Qu, X., Xia, C., Huang, K., Xie, F., Wang, N., Wei, X., & Jia, Q. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110390 · Cited by 35
Pleiotropic effects of DCLK1 in cancer and cancer stem cells
Chhetri, D., Vengadassalapathy, S., Venkadassalapathy, S., Balachandran, V., Umapathy, V. R., Veeraraghavan, V. P., Jayaraman, S., Patil, S., Iyaswamy, A., Palaniyandi, K., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.965730 · Cited by 34
“Chemotherapy-resistant CSCs are precursors to CRC recurrence (Das et al., 2020).”
BackgroundMitochondria in colorectal cancer stem cells - a target in drug resistance
Rainho, M. D. A., Siqueira, P. B., de Amorim, Í. S. S., Mencalha, A. L., & Thole, A. A. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.116 · Cited by 34
Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer
Haque, M., Shyanti, R. K., & Mishra, M. K. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1431418 · Cited by 33
Wang, R., Wang, Y., Liu, X., Liu, M., Sun, L., Pan, X., Hu, H., Jiang, B., Zou, Y., Liu, Q., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05916-8 · Cited by 33
Genome editing via non-viral delivery platforms: current progress in personalized cancer therapy
Lan, T., Que, H., Luo, M., Zhao, X., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01550-8 · Cited by 32
Exosomes derived from cancer-associated fibroblasts mediate response to cancer therapy
Masoudi-Khoram, N., Soheilifar, M. H., Ghorbanifar, S., Nobari, S., Hakimi, M., & Hassani, M. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103967 · Cited by 31
The Impact of Cancer Stem Cells in Colorectal Cancer
Radu, P., Zurzu, M., Tigora, A., Paic, V., Bratucu, M., Garofil, D., Surlin, V., Munteanu, A. C., Coman, I. S., Popa, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084140 · Cited by 30
Beyond chemotherapy: Exploring 5-FU resistance and stemness in colorectal cancer
Singh, U., Kokkanti, R. R., & Patnaik, S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177294 · Cited by 30
Taib, N., Merhi, M., Inchakalody, V. P., Mestiri, S., Hydrose, S., Makni‐Maalej, K., Raza, A., Sahir, F., Azizi, F., Nizamuddin, P. B., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04073-y · Cited by 30
Liu, Z., Zhang, T., Ye, X., Liu, Z., Sun, X., Zhang, L.-L., & Wu, C. (2022) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgab130 · Cited by 29
Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors
Guo, L., Mohanty, A. R., Singhal, S. S., Srivastava, S., Nam, A., Warden, C., Ramisetty, S. K., Yuan, Y., Cho, H., Wu, X., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107302 · Cited by 29
Impact of Non-Coding RNAs on Chemotherapeutic Resistance in Oral Cancer
Yamaguchi, K., Yamamoto, T., Chikuda, J., Shirota, T., & Yamamoto, Y. (2022) · Biomolecules · doi:10.3390/biom12020284 · Cited by 28
Nojima, Y., Yao, R., & Suzuki, T. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167693 · Cited by 28
Brun, S., Pascussi, J., Gifu, E. P., Bestion, E., Jílková, Z. M., Wang, G., Bassissi, F., Mezouar, S., Courcambeck, J., Merle, P., et al. (2021) · Journal of Cancer · doi:10.7150/jca.58533 · Cited by 27
Curcumin, calebin A and chemosensitization: How are they linked to colorectal cancer?
Brockmueller, A., Samuel, S. M., Mazuráková, A., Büsselberg, D., Kubatka, P., & Shakibaei, M. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121504 · Cited by 27
Sun, J., Zhou, H., Bao, X., Wu, Y., Jia, H., Zhao, H., & Liu, G. (2021) · Stem Cells International · doi:10.1155/2021/1075481 · Cited by 27
“CSCs are the major cause of chemoresistance and cancer recurrence in CRC treatment [28].”
BackgroundXu, L., Cai, P., Li, X., Wu, X., Gao, J., Liu, W., Yang, J., Xu, Q., Guo, W., & Gu, Y. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115672 · Cited by 26
Comprehensive Review on the Effect of Stem Cells in Cancer Progression
Das, S., Khan, T. H., & Sarkar, D. (2024) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-024-00053-6 · Cited by 26
Therapeutic Strategies Against Cancer Stem Cells in Esophageal Carcinomas
Das, P. K., Islam, F., Smith, R. A., & Lam, A. K.-Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.598957 · Cited by 26
Self-citationWang, S., Cheng, L., Wu, H., & Li, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.949656 · Cited by 26
Bhattacharjya, D., & Sivalingam, N. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03189-2 · Cited by 25
“Notch activation is crucial for maintaining CSC phenotypic traits, and blocking Notch signaling with DAPT in vitro inhibited cell proliferation and reduced chemo-resistant and ionosphere cell numbers (Das et al. 2020).”
PARP-1 Expression Influences Cancer Stem Cell Phenotype in Colorectal Cancer Depending on p53
Puentes-Pardo, J. D., Moreno-SanJuan, S., Casado, J., Escudero-Feliú, J., López-Pérez, D., Sánchez-Uceta, P., González-Novoa, P., Gálvez, J., Carazo, Á., & León, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054787 · Cited by 24
“The latter two factors have been associated with the presence of cancer stem cells (CSCs), a small subset of cancer cells also considered as the root for cancer initiation and metastasis [3].”
BackgroundMicrophysiological systems to study colorectal cancer: state-of-the-art
Ramos, P., Carvalho, M. R., Chen, W., Yan, L., Zhang, C., He, Y., Reis, R. L., & Oliveira, J. M. (2023) · Biofabrication · doi:10.1088/1758-5090/acc279 · Cited by 24
“Importantly, CSCs, with an enhanced self-renewal capacity, are also regarded as a niche of resistance due to an upregulation of growth signalling pathways such as Wnt, Notch, Hedgehog and Hyppo/Yap [102].”
BackgroundRío-Vilariño, A., Cenigaonandia‐Campillo, A., García-Bautista, A., Mateos‐Gómez, P. A., Schlaepfer, M. I., del Puerto‐Nevado, L., Aguilera, O., García‐García, L., Galeano, C., de Miguel, I., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02649-z · Cited by 24
Cao, Y., Lu, C., Beeraka, N. M., Efetov, S. K., Enikeev, M. E., Fu, Y., Yang, X., Basappa, B., He, M., & Li, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1428920 · Cited by 24
“…metabolism, changes in gene expression, metabolic reprogramming, stemness development, and changes in cell death pathways are signi fi cant in fl uential factors which have been implicated in chemotherapy resistance (194 – 196), however, the precise underlying mechanisms remain unclear.”
BackgroundMare, M., Colarossi, L., Veschi, V., Turdo, A., Giuffrida, D., Memeo, L., Stassi, G., & Colarossi, C. (2021) · Genes · doi:10.3390/genes12101502 · Cited by 24
Alkahtani, S. H., Alarifi, S. A., Albasher, G. I., Al-Zharani, M. M., Aljarba, N. H., Almarzoug, M. H. A., Alhoshani, N. M., AL–Johani, N. S., Alothaid, H., & Alkahtane, A. A. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5834418 · Cited by 23
Jia, Q.-Y., Zhu, Y., Yao, H., Yin, Y., Duan, Z., Zheng, J.-H., Ma, D., Yang, M., Yang, J., Zhang, J., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07110-w · Cited by 22
“Furthermore, we de fi ned the patients with a score ≤ 4 as the low GALNT5 expression group and the patients with a score > 4 as the high GALNT5 expression group.”
BackgroundKobecki, J., Gajdzis, P., Mazur, G. J., & Chabowski, M. (2022) · Diagnostics · doi:10.3390/diagnostics12123076 · Cited by 22
Re-Sensitizing Cancer Stem Cells to Conventional Chemotherapy Agents
Kim, M., Bakyt, L., Akhmetkaliyev, A., Toktarkhanova, D., & Bulanin, D. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032122 · Cited by 22
Wang, Y., Yang, Z., Zhu, W., Chen, Y., He, X., Li, J., Han, Z., Yang, Y., Liu, W., & Zhang, K. (2023) · Drug Development Research · doi:10.1002/ddr.22067 · Cited by 21
“It is known that the maintenance of CSLCs traits including self‐ renewal, multipotential differentiation, and tumorigenicity, is closely related to abnormal activation of stemness‐associated signaling, such as Wnt and PI3K/AKT/mTOR (Das et al., 2020).”
BackgroundInfluentialLawler, T., Parlato, L., & Andersen, S. W. (2023) · Cancer Causes & Control · doi:10.1007/s10552-023-01783-y · Cited by 21
“…able to avoid chemoradiation-induced apoptotic cell death by increasing the expression of DNA repair enzymes, scavenging reactive oxygen species via the expression of antioxidant enzymes (e.g., superoxide dismutase, catalase, and glutathione peroxidase), and activating cell cycle checkpoints [142].”
Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
Cao, J., Zhang, Z., Zhou, L., Luo, M., Li, L., Li, B., Nice, E. C., He, W., Zheng, S., & Huang, C. (2023) · MedComm · doi:10.1002/mco2.427 · Cited by 21
Ji, D., Jia, J., Cui, X., Li, Z., & Wu, A. (2023) · iScience · doi:10.1016/j.isci.2023.106600 · Cited by 21
“For example, oxaliplatin treatment of xenograft colon cancer cells showed an increase in CD133+ tumor cells.(43) These characteristics of stem cells may be related to multidrug resistance (MDR), cell cycle dormancy, decreased levels of reactive oxygen species (ROS), and DNA repair mechanisms.”
BackgroundFu, F., Chen, L., Yang, X., Fan, L., Zhang, M., Chen, S., Zheng, M., Gao, M., & Zhang, S. (2022) · Journal of Cancer · doi:10.7150/jca.74211 · Cited by 20
Ruiz‐Malagón, A. J., Hidalgo‐Garcia, L., Rodríguez‐Sojo, M. J., Molina‐Tijeras, J. A., García, F., Diez‐Echave, P., Vezza, T., Becerra, P., Marchal, J. A., Redondo‐Cerezo, E., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114760 · Cited by 20
The SOX9-MMS22L Axis Promotes Oxaliplatin Resistance in Colorectal Cancer
Liu, Y., Wu, H., Luo, T., Luo, Q., Meng, Z., Shi, Y. K., Li, F., Liu, M., Peng, X., Liu, J., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.646542 · Cited by 19
“Studies have confirmed that SOX9-overexpressing cancer cells are resistant to oxaliplatin (Anuja et al., 2019; Qian et al., 2019; Abad et al., 2020; Das et al., 2020).”
BackgroundEpigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors
Grumetti, L., Lombardi, R., Iannelli, F., Pucci, B., Avallone, A., Gennaro, E. D., & Budillon, A. (2022) · Cancers · doi:10.3390/cancers14030695 · Cited by 19
Bimetallic Coordination Polymers: Synthesis and Applications in Biosensing and Biomedicine
Sun, Y., Ma, J., Ahmad, F., Xiao, Y.-L., Guan, J., Shu, T., & Zhang, X. (2024) · Biosensors · doi:10.3390/bios14030117 · Cited by 18
“For cancer treatment, traditional cancer drugs and cancer vaccines as well as emerging functional nanomaterials (light-sensitive, heat-sensitive, and microwave-sensitive materials) are effective therapies [158].”
BackgroundGharehbaba, A. M., Soltanmohammadi, F., Vandghanooni, S., Eskandani, M., & Adibkia, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118045 · Cited by 18
Tailoring a novel colorectal cancer stem cell-targeted therapy by inhibiting the SMYD3/c-MYC axis
Signorile, M. L., Nicola, E. D., Forte, G., Sanese, P., Fasano, C., Disciglio, V., Marco, K. D., Latrofa, M., Cecco, L. D., Ficorilli, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02290-z · Cited by 18
“6 Moreover, following primary tumor growth, CRC-SCs are implicated in recurrence and metastatic dissemination through dormancy, re-initiation, and escape from immune surveillance mechanisms.”
Shen, Y., Ni, S., Li, S., & Lv, B. (2023) · Cancer Medicine · doi:10.1002/cam4.5833 · Cited by 17
Soman, S., Kulkarni, S., Vineeth, P. S., George, S. D., & Mutalik, S. (2024) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2024.101360 · Cited by 17
Chen, Y., Yang, Z., He, X., Zhu, W., Wang, Y., Li, J., Han, Z., Wen, J., Liu, W., Yang, Y., et al. (2023) · Environmental Toxicology · doi:10.1002/tox.23924 · Cited by 17
“26 Our results revealed that PC repressed the ability of tumorsphere and colony formation in CRC cells, suggesting that PC suppressed phenotype transformation of CCSCs.”
BackgroundLi, Y., Huo, J., He, J., & Ma, X. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01911-1 · Cited by 17
Molecular Biomarkers and Signaling Pathways of Cancer Stem Cells in Colorectal Cancer
Omran, M. M., Fouda, M. S., Mekkawy, S. A., Tabll, A. A., Abdelaziz, A. G., Omran, A. M., & Emran, T. M. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241254061 · Cited by 16
“12 So, this review is mostly about the current state of CRCSC biomarkers and the pathways linked to the growth of CRC from the point of view of the CSC model.”
BackgroundRocha, M. R., Castillo‐Medina, Y. K., Coelho, B. M. D. L., Rios, L. L. L., & Morgado‐Díaz, J. A. (2024) · Cell Biology International · doi:10.1002/cbin.12270 · Cited by 16
Roles of microRNAs in Gastrointestinal Cancer Stem Cell Resistance and Therapeutic Development
Hwang, G.-R., Yuen, J. G., & Ju, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041624 · Cited by 15
“Although the origin of CRC CSCs is still debated today, ultimately, among several other pathways, dysregulations within the Wnt [36], Notch, and TGF- signaling pathways of the intestinal epithelial cells have all been found to contribute to the stemness of CRC CSCs [2,33,35,37].”
BackgroundTajik, F., Fattahi, F., Rezagholizadeh, F., Bouzari, B., Babaheidarian, P., Wadji, M. B., & Madjd, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-46484-3 · Cited by 15
Colorectal Cancer Stem Cell Biomarkers: Biological Traits and Prognostic Insights
Soleimani, A., Saeedi, N., Al-Asady, A. M., Nazari, S. E., Hanaie, R., Khazaei, M., Ghorbani, E., Akbarzade, H., Ryzhikov, M., Avan, A., et al. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128291321240329050945 · Cited by 15
Wu, J., Li, W., Su, J., Zheng, J., Liang, Y., Lin, J., Xu, B., & Liu, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-62913-3 · Cited by 15
Gupta, K., Jones, J. C., Farias, V., Mackeyev, Y., Singh, P. K., Quiñones‐Hinojosa, A., & Krishnan, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.840241 · Cited by 15
Zhang, X. X., Xiao, Y., Yan, Y. Y., Wang, Y., Jiang, H., Wu, L., Shi, J., & Liu, X. H. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00820 · Cited by 15
Polverini, P. J., Nör, F., & Nor, J. E. (2023) · Frontiers in Oral Health · doi:10.3389/froh.2022.1095842 · Cited by 15
Advances of nanotechnology applied to cancer stem cells
Yue, M., Guo, T., Nie, D., Zhu, Y.-X., & Lin, M. (2023) · World Journal of Stem Cells · doi:10.4252/wjsc.v15.i6.514 · Cited by 15
Metadata
- Authors
- Das, P. K., Islam, F., & Lam, A. K.
- Affiliations
- University of Rajshahi (BD)
- Griffith University (AU)
- Corresponding author
- Islam, Farhadul
- Lam, Alfred K.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-06-03
- Volume
- 9
- Issue
- 6
- Pages
- 1392
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7348976
- OpenAlex
- W3033624893
- Cited by
- 210
- References
- 119
- Citations by year
- 2026: 12 · 2025: 29 · 2024: 42 · 2023: 47 · 2022: 48 · 2021: 27 · 2020: 5
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Griffith Research Online (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- cancer stem cells, colorectal cancer, treatment resistance, Wnt/β-catenin signaling, Notch signaling, Hedgehog signaling, Hippo/YAP signaling, PI3K/Akt signaling, DNA repair, reactive oxygen species scavenging, cell cycle checkpoints, microRNA, metabolic reprogramming, chemoradiotherapy, self-renewal
- MeSH terms
- Animals, DNA Damage, Humans, Neoplastic Stem Cells, Colorectal Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, MicroRNAs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.